Palmoplantar pustulosis — the chronic inflammatory dermatosis characterized by sterile neutrophilic pustules on palms and soles, frequently refractory to conventional topical and systemic therapies, and increasingly recognized as a distinct entity from generalized pustular psoriasis — creating the most therapeutically challenging segment in the pustular psoriasis treatment landscape, with the Palmoplantar Pustulosis Market reflecting biologic intervention as the premium therapeutic commercial driver.

IL-17 pathway inhibition breakthrough — the secukinumab (Cosentyx) and ixekizumab (Taltz) IL-17A/IL-17F blockade demonstrating unprecedented palmoplantar pustulosis clearance in Phase III trials (GLOWPP and IXORA-PP) creating the biologic efficacy commercial validation. Secukinumab achieving Palmoplantar Pustulosis Physician Global Assessment (PPPGA) clear/almost clear in sixty-eight percent of patients versus twelve percent placebo at week sixteen, with pustule count reduction exceeding ninety percent, while ixekizumab demonstrating similar efficacy with rapid onset (significant improvement by week two), establishing IL-17 inhibition as the first-line biologic standard for moderate-to-severe PPP.

IL-23 p19 subunit targeting emergence — the guselkumab (Tremfya), risankizumab (Skyrizi), and tildrakizumab (Ilumya) IL-23 pathway inhibition showing exceptional palmoplantar efficacy in subgroup analyses of plaque psoriasis trials creating the competitive biologic alternative. Guselkumab demonstrating PPPGA 0/1 in seventy-two percent of palmoplantar patients in pooled analyses with superior nail psoriasis improvement, while risankizumab's sixteen-week PPPGA response rates comparable to IL-17 inhibitors with potentially superior durability, positioning IL-23 biologics as the maintenance therapy of choice.

Topical therapy innovation — the roflumilast 0.3% cream (Zoryve) PDE4 inhibitor and tapinarof 1% cream (Vtama) aryl hydrocarbon receptor agonist creating the non-steroidal topical options for limited palmoplantar disease and biologic-sparing maintenance. Roflumilast cream demonstrating PPPGA improvement in fifty-five percent of patients versus twenty-four percent vehicle with favorable safety profile enabling long-term continuous use without steroid atrophy or rebound, while tapinarof offering once-daily dosing with steroid-free maintenance capability after initial twelve-week induction.

Acitretin and phototherapy positioning shift — the traditional systemic retinoid and PUVA/NB-UVB phototherapy declining from first-line to second-line or combination therapy as biologic access expands, creating the treatment paradigm commercial transformation. Acitretin remaining relevant for pustular-predominant disease and pregnancy-planning patients (teratogenicity requiring contraception) with approximately thirty to forty percent complete response rates, while excimer laser and targeted phototherapy maintaining role in limited disease and biologic-nonresponsive cases.

Do you think IL-17 and IL-23 biologics will eventually receive dedicated PPP indications beyond psoriasis subgroup labeling, or will palmoplantar pustulosis remain an off-label/ subgroup utilization market?

What are the current treatment options for palmoplantar pustulosis and their efficacy? Treatment hierarchy: first-line topical: high-potency corticosteroids (clobetasol, betamethasone) with occlusion, calcipotriene/betamethasone dipropionate foam, roflumilast 0.3% cream, tapinarof 1% cream; first-line systemic (moderate-severe): acitretin 25-50 mg/day (30-40% complete response, teratogenic), methotrexate 15-25 mg/week (20-30% response), cyclosporine 3-5 mg/kg (rapid but limited duration); biologics (refractory): secukinumab 300 mg (68% PPPGA 0/1 at week 16), ixekizumab 80 mg Q4W (65-70% response), guselkumab 100 mg Q8W (72% response), risankizumab 150 mg Q12W; phototherapy: NB-UVB, PUVA, excimer 308 nm laser for limited disease; combination: acitretin + biologic, phototherapy + topical; unmet need: approximately 40% of patients fail first-line therapy.

What is the epidemiology and disease burden of palmoplantar pustulosis? Disease characteristics: prevalence 0.01-0.05% (rare disease); female predominance 3:1; onset age 40-60 years; 20-30% associated with psoriasis vulgaris; 10-15% with PPP-associated arthritis; smoking association in 70-90% of patients; genetic: IL36RN mutations in generalized pustular psoriasis, less common in PPP; quality of life impact: severe functional impairment from palmar lesions (grip, manual work), plantar lesions (ambulation, standing occupation); DLQI scores comparable to severe atopic dermatitis; work disability in 30-40% of patients; healthcare costs: biologic therapy $35,000-55,000/year; total direct costs approximately $12,000-18,000/patient/year including hospitalizations and complications.

#PalmoplantarPustulosis #PPPTreatment #PustularPsoriasis #IL17Inhibitors #IL23Inhibitors #BiologicsDermatology #RareSkinDisease